If approved, deucravacitinib would become the first tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease, said BMS, which is hoping to position the new drug as the treatment of choice for people with moderate to severe plaque psoriasis who want an orally-active option.
BMS has said it think deucravacitinib could become a $4 billion product at peak, despite a recent setback when it failed a phase 2 trial in follow-up indication ulcerative colitis.
